Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 836880 in advanced solid tumors
NCT02689505Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2016
- Primary completion
- Jul 2019
- Modality
- Bispecific Antibodies, Nanobodies (VHH)
- Countries
- 2
01
Overview
Phase 1, open-label trial of BI 836880 in Neoplasm (5 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Maximum Tolerated Dose at 3 weeks and Dose Limiting Toxicities at 3 weeks. Started Apr 2016; status: completed.
02
Drugs
BI 836880
03
Conditions
Neoplasm
Beyond the preview
Go deeper on NCT02689505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02689505.